Chlormethine Gel (Ledaga)


 CADTH recommends that Ledaga should not be reimbursed by public drug plans for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients who have received prior skin-directed therapy.
 Although evidence from a clinical trial found was inferior to chlormethine ointment, ointment is used Canada. There no show whether works better than or similar treatments MF-CTCL are currently Canada.
 an unmet need with fewer side effects, but it remains unknown has effects compared other